I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again.

Richard James Whitley net worth and biography

Richard Whitley Biography and Net Worth

Director of Gilead Sciences

Dr. Richard James Whitley M.D. serves as Independent Director of the Company. Dr. Whitley is the Distinguished Professor, Loeb Scholar Chair in Pediatrics, and Professor of Pediatrics, Microbiology, Medicine and Neurosurgery at the University of Alabama at Birmingham. He is the Co-Director, Division of Pediatric Infectious Diseases; Vice-Chair, Department of Pediatrics; Senior Scientist, Department of Gene Therapy; Director for Drug Discovery and Development; Senior Leader, Comprehensive Cancer Center; Associate Director for Clinical Studies, Center for AIDS Research; and Co-Founder and Co-Director, Alabama Drug Discovery Alliance. Dr. Whitley is responsible for the National Institute of Allergy and Infectious Diseases (NIAID) Collaborative Antiviral Study Group and directs a center for drug discovery in the arena of emerging infections. He is a past President of the International Society of Antiviral Research and the Infectious Diseases Society of America, and currently chairs both the NIAID Recombinant DNA Advisory Council and the NIAID HIV Vaccine Data Safety and Management Board. He is an elected member of the American Society of Clinical Investigation, the Association of American Physicians and an Honorary member of the Irish Academy of Science.

What is Richard James Whitley's net worth?: The estimated net worth of Richard James Whitley is at least $63,133.00 as of December 8th, 2022. Dr. Whitley owns 700 shares of Gilead Sciences stock worth more than $63,133 as of November 23rd. This net worth approximation does not reflect any other assets that Dr. Whitley may own. Learn More about Richard James Whitley's net worth.
How do I contact Richard James Whitley?: The corporate mailing address for Dr. Whitley and other Gilead Sciences executives is 333 LAKESIDE DRIVE, FOSTER CITY CA, 94404. Gilead Sciences can also be reached via phone at (650) 574-3000 and via email at [email protected]. Learn More on Richard James Whitley's contact information.
Has Richard James Whitley been buying or selling shares of Gilead Sciences?: Richard James Whitley has not been actively trading shares of Gilead Sciences over the course of the past ninety days. Most recently, Richard James Whitley sold 20,282 shares of the business's stock in a transaction on Monday, May 3rd. The shares were sold at an average price of $64.57, for a transaction totalling $1,309,608.74. Following the completion of the sale, the director now directly owns 51,404 shares of the company's stock, valued at $3,319,156.28. Learn More on Richard James Whitley's trading history.
Who are Gilead Sciences' active insiders?: Gilead Sciences' insider roster includes Gregg Alton (EVP), Paul Carter (EVP), John Cogan (Director), Andrew Dickinson (Exec. VP & CFO ), Andrew Dickinson (CFO), John Martin (Director), Johanna Mercier (Insider), James Meyers (EVP), John Milligan (Insider), Daniel O'Day (Chairman & CEO ), Merdad Parsey (Insider), Brett Pletcher (EVP), Javier Rodriguez (Director), Robin Washington (CFO), Richard Whitley (Director), and Diane Wilfong (CAO). Learn More on Gilead Sciences' active insiders.
Are insiders buying or selling shares of Gilead Sciences?: In the last year, insiders at the biopharmaceutical company sold shares 9 times. They sold a total of 81,679 shares worth more than $6,935,730.32. The most recent insider tranaction occured on November, 6th when insider Merdad Parsey sold 25,590 shares worth more than $2,341,485.00. Insiders at Gilead Sciences own 0.2% of the company. Learn More about insider trades at Gilead Sciences.
Information on this page was last updated on 11/6/2024.

Richard James Whitley Insider Trading History at Gilead Sciences

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
5/3/2021	Sell	20,282	$64.57	$1,309,608.74	51,404
4/1/2019	Sell	9,534	$65.48	$624,286.32	34,669
3/2/2015	Sell	5,000	$103.43	$517,150.00
1/2/2015	Sell	5,000	$95.22	$476,100.00
11/3/2014	Sell	5,000	$112.02	$560,100.00
10/1/2014	Sell	5,000	$106.99	$534,950.00
8/1/2014	Sell	5,000	$91.00	$455,000.00
7/1/2014	Sell	5,000	$83.65	$418,250.00
6/2/2014	Sell	5,000	$80.95	$404,750.00
5/1/2014	Sell	5,000	$78.63	$393,150.00	12,778

Richard James Whitley Buying and Selling Activity at Gilead Sciences

Gilead Sciences Company Overview

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. The company has collaboration agreements with Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Dragonfly Therapeutics, Inc.; Arcellx, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company was incorporated in 1987 and is headquartered in Foster City, California.

Today's Range

Now: $90.19

$89.27

$90.49

50 Day Range

MA: $87.43

$82.21

$97.90

2 Week Range

Now: $90.19

$62.07

$98.90

Volume

4,545,876 shs

Average Volume

7,529,191 shs

Market Capitalization

$112.40 billion

P/E Ratio

1,002.11

Dividend Yield

3.43%

Beta

0.17

Trump won. Buy this coin now.

From Weiss Ratings | Ad

Juan Villaverde called the top and bottom of every crypto bull market since 2012. He believes Bitcoin will go to $150,000 — or more. But there’s one coin he thinks could go even higher.

This could be his favorite coin.